AI-based drug discovery company Recursion raises $239M Series D and partners with pharma giant Bayer to develop new treatments for fibrotic diseases (Leah Rosenbaum/Forbes)

Leah Rosenbaum / Forbes:
AI-based drug discovery company Recursion raises $239M Series D and partners with pharma giant Bayer to develop new treatments for fibrotic diseases  —  Startups that want to leverage artificial intelligence in drug discovery are a dime a dozen in today's biotech landscape.